{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:26:04Z","timestamp":1725625564631},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.medcli.2013.04.038","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T08:37:16Z","timestamp":1372927036000},"page":"360-364","source":"Crossref","is-referenced-by-count":4,"title":["Indicaciones terap\u00e9uticas actuales de la talidomida y la lenalidomida"],"prefix":"10.1016","volume":"142","author":[{"given":"Josep","family":"Ordi-Ros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Cosiglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.04.038_bib0005","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM196212062672305","article-title":"The saga of thalidomide: Neuropathy to embryopathy, with case reports and congenital abnormalities","volume":"23","author":"Mellin","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.038_bib0010","first-page":"65","article-title":"Thalidomide revisited","volume":"13","author":"D\u2019Arcy","year":"1994","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"10.1016\/j.medcli.2013.04.038_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/chir.530070109","article-title":"Sterospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide","volume":"7","author":"Eriksson","year":"1995","journal-title":"Chirality"},{"key":"10.1016\/j.medcli.2013.04.038_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.medcli.2013.04.038_bib0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0190-9622(84)80458-2","article-title":"Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes","volume":"11","author":"Barnhill","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/bmj.313.7054.377","article-title":"New roles for thalidomide: A unique anti-inflammatory, but use it only when no alternatives exist","volume":"313","author":"Powell","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2013.04.038_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1086\/314842","article-title":"Protein kinase C-dependent effects on leukocyte migration of thalidomide","volume":"180","author":"Meierhofer","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medcli.2013.04.038_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.038_bib0045","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","article-title":"Thalidomide for the treatment of chronic graft-versus-host disease","volume":"326","author":"Vogelsang","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.038_bib0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.1991.tb04377.x","article-title":"Thalidomide treatment for chronic graft-versus-host disease","volume":"78","author":"Heney","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1005770612294","article-title":"An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action","volume":"15","author":"Gradishar","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.medcli.2013.04.038_bib0060","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: Dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br JDermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0065","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/jm9603328","article-title":"Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity","volume":"39","author":"Muller","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.medcli.2013.04.038_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0075","doi-asserted-by":"crossref","first-page":"513702","DOI":"10.1155\/2012\/513702","article-title":"Molecular action of lenalidomide in lymphocytes and hematologic malignancies","volume":"2012","author":"McDaniel","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.medcli.2013.04.038_bib0085","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","article-title":"The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum","volume":"168","author":"Sampaio","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medcli.2013.04.038_bib0090","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1086\/498216","article-title":"Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation","volume":"192","author":"Haslett","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medcli.2013.04.038_bib0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.47276\/lr.78.3.197","article-title":"The role of thalidomide in the management of erythema nodosum leprosum","volume":"78","author":"Walker","year":"2007","journal-title":"Lepr Rev"},{"key":"10.1016\/j.medcli.2013.04.038_bib0100","first-page":"537","article-title":"Current role of thalidomide in HIV-positive patients with recurrent aphthous ulcerations","volume":"55","author":"Shetty","year":"2007","journal-title":"Gen Dent"},{"key":"10.1016\/j.medcli.2013.04.038_bib0105","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1086\/515222","article-title":"Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial","volume":"28","author":"Ramirez-Amador","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2013.04.038_bib0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0248-8663(99)80105-2","article-title":"Treatment of recurrent ulceration with low doses of thalidomide","volume":"20","author":"De Wazi\u00e8res","year":"1999","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.medcli.2013.04.038_bib0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02054255","article-title":"Treatment of Beh\u00e7et's disease with thalidomide","volume":"5","author":"Hamza","year":"1986","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: Update of therapeutic options. Part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0125","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/archderm.1975.01630230050009","article-title":"Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus","volume":"111","author":"Prystowsky","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2133.2011.10693.x","article-title":"Thalidomide in the treatment of refractory cutaneous lupus erythematosus: Prognostic factors of clinical outcome","volume":"166","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0135","first-page":"158","article-title":"Treatment of refractory rheumatoid arthritis--The thalidomide experience","volume":"16","author":"Guti\u00e9rrez-Rodr\u00edguez","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0140","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/ard.55.11.833","article-title":"An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis","volume":"55","author":"Huizinga","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2013.04.038_bib0145","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","article-title":"Thalidomide for treatment of patients with chronic graft-versus-host disease","volume":"96","author":"Koc","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.038_bib0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5045\/kjh.2011.46.3.153","article-title":"Treatment of chronic graft-versus-host disease: Past, present and future","volume":"46","author":"Martin","year":"2011","journal-title":"Korean J Hematol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0155","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","article-title":"Pyoderma gangrenosum: An updated review","volume":"23","author":"Ruocco","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0160","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1067\/mjd.2001.113477","article-title":"Effectors of inflammation in actinic prurigo","volume":"44","author":"Arrese","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0165","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1365-4362.2003.01184.x","article-title":"Treatment of prurigo nodularis with thalidomide: A case report and review of the literature","volume":"42","author":"Alfadley","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","article-title":"Thalidomide and its derivates: Emerging from the wilderness","volume":"79","author":"Gordon","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.medcli.2013.04.038_bib0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivates as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.medcli.2013.04.038_bib0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/107327480301000504","article-title":"Thalidomide and its derivatives: New promise for multiple myeloma","volume":"10","author":"Weber","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.medcli.2013.04.038_bib0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0095-5108(18)30810-8","article-title":"The thalidomide syndrome: Risks of exposure and spectrum of malformations","volume":"13","author":"Newman","year":"1986","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0190","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1096-9926(200012)62:6<432::AID-TERA11>3.0.CO;2-Z","article-title":"The re-emergence of thalidomide: Results of a scientific conference","volume":"62","author":"Neiger","year":"2000","journal-title":"Teratology"},{"key":"10.1016\/j.medcli.2013.04.038_bib0195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0200","first-page":"11","article-title":"Thalidomide in multiple myeloma","volume":"13","author":"Rajkumar","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.medcli.2013.04.038_bib0205","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Risk factors for deep vein thrombosis in a large group of myeloma patients treated with thalidomide: The Arkansas experience","volume":"98","author":"Zargari","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.038_bib0210","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/pgmj.70.830.901","article-title":"Guideline for the clinical use and dispensing of thalidomide","volume":"70","author":"Powell","year":"1994","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.medcli.2013.04.038_bib0215","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexametasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.038_bib0220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.038_bib0225","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1179\/102453310X12647083620921","article-title":"Lenalidomide: A synthetic compound with an evolving role in cancer management","volume":"15","author":"Saloura","year":"2010","journal-title":"Hematology"},{"key":"10.1016\/j.medcli.2013.04.038_bib0230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/107327481201900106","article-title":"Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia","volume":"19","author":"Carballido","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.medcli.2013.04.038_bib0235","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archdermatol.2011.2918","article-title":"Treatment of refractory prurigo nodularis with lenalidomide","volume":"148","author":"Kanavy","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0240","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaad.2011.01.015","article-title":"Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare","volume":"66","author":"Braunstein","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0245","first-page":"172","article-title":"Successful treatment of Beh\u00e7et's disease with lenalidomide","volume":"158","author":"Green","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.medcli.2013.04.038_bib0250","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1749-6632.2011.05974.x","article-title":"A review of the history, properties, and use of the immunomodulatory compound lenalidomide","author":"Zeldis","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.medcli.2013.04.038_bib0255","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase iii trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2013.04.038_bib0260","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.038_bib0265","unstructured":"Comunicado de la FDA sobre la seguridad de los medicamentos: Informe actualizado sobre la seguridad del medicamento Revlimid (lenalidomida) para el c\u00e1ncer y el riesgo de nuevos tipos de neoplasias (nuevos tipos de c\u00e1ncer). U.S. Food and Drug Administration. [En l\u00ednea]. 2012. [consultado Nov 2012]. Disponible en: http:\/\/www.fda.gov"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T09:01:41Z","timestamp":1645952501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313003291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0025775313003291"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.04.038","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}